Lisa Butterfield, Cancer Immunotherapy Consultant and Advisory Board Member, shared on LinkedIn:
“The latest cancer vaccine news from Merck-Moderna and from BioNTech-Genentech has the IO field keeping our eyes open for the data while we hypothesize about the reasons for the different outcomes.
I’ve updated my slides twice and look forward to a creative discussion this week in Lausanne.
Read more here.”
Make sure you do not miss: SITC 2026 EU Immuno-Oncology Summit Coming to Switzerland
